laboratori corpor
remain bullish follow result mark solid core trend launchpad
progress cro margin expans robust attract guidanc
despit hand headwind pama beaconlb contract core
lab trend remain solid continu view lh intermediate/long-
term strateg posit high quality/low cost provid enviabl
addit like complementari model consum friendli initi
strong financi flexibl provid meaning firepow on-going capit
deploy reiter buy pt ep vs prior
pictur trend lab busi remain solid volum better
expect vs strhe acquisit organ
revenu per requisit grew ex-disposit vs strhe
posit acquisit relat mix/low consum genet demand
off-set pama bp non-renew beaconlb bp
expect pama headwind persist impact contract
chang mitig on-going launchpad progress provid off-set
continu think ramp prefer lab network
buy provid share gain opportun potenti halo effect
time given role clinic diagnost healthcar decision-
make remain bullish fundament lab busi expect
high quality/low cost provid lh disproport benefit
focu valu continu intensify/narrow prefer network becom
preval also expect ongoing/potenti acceler opportun
around share gain strateg continu reimburs
pressur pama disproportion weigh smaller less sophist
drug develop busi roll along covanc revenu
modestli think growth acquisit
organ quarter impact disposit bp
neg fx translat bp organ revenu grew mid-to-high singl
digit ex pass-through addit margin expand bp yoy
launchpad save acquisit off-set personnel cost ttm
net-book-to-bil grew net order backlog exit
 expect convert next month
earli develop remain area strength covanc seen
strong traction small-to-mid size biotech compani continu
see addit opportun big pharma oncolog focu given lh
tr target
laboratori corpor america hold
uniqu combin platform scope integr data analyt capabl heighten focu
oncolog technolog solut improv efficiency/streamlin trial view covanc well
posit drive on-going strong growth guidanc call revenu growth
solid result guidanc bracket strh/consensu net revenu came
touch ahead consensu tie perform lab busi
vs strhe slightli lower revenu drug develop vs strhe
top line coupl roughli in-lin margin vs strhe better gross
margin launchpad save acquisit off-set higher sg personnel cost cyber secur
invest adjust ebit in-lin oper result aid better
line item includ lower tax result adjust ep five cent ahead
compani provid guidanc includ consolid revenu growth lab revenu
growth drug develop revenu growth lh also expect
adjust ep vs strhe consensu free cash flow
 rais revenu
ep unchang
remain strong cffo come ahead
estim lh bought back stock spent acquisit
compani exit year cash debt debt-to-ebitda ratio
strong balanc sheet guidanc call financi flexibl
remain high compani expect continu deploy capit strateg share
repurchas pama pressur weigh expect pipelin opportun remain
robust/potenti acceler remain bullish lh continu like complementari
busi model see attract opportun on-going capit deploy rais price
target ep vs prior reiter buy rate
page
laboratori corpor america hold
laboratori corpor america mm
servic
revenu
incom equiti invest
revenu
page
laboratori corpor america hold
headquart burlington nc laboratori corpor america hold labcorp one
largest independ clinic laboratori broad offer includ routin test
blood chemistri urinalys pap hiv substance-abus etc specialti test oncolog hiv
genotyp phenotyp diagnost genet clinic research trial compani also
oper cro busi extend servic offer includ clinic research provid
meaning intern presenc chiltern acquisit meanin expand cro servic
clinic lab remain integr part healthcar deliveri model diagnost test critic
compon treatment decis process combin covanc busi lh boast
signific scale divers servic offer uniqu posit area person medicin
potenti risk-bas reimburs system diversifi revenu stream custom
base also meaning lower reimburs risk one custom repres revenu
govern pay manag addit signific clinic horsepow geograph
diversif provid platform addit growth opportun time rate share buy
valuat risk
price target base stock trade adjust ep premium
current multipl given labcorp sizabl esoter presenc solid cash flow gener
attract cross-sel opportun covance/chiltern view appropri addit
believ effici initi aggress focu cost control could provid
support think shift valu inher favor scale sophist provid risk
rate price target includ advers shift reimburs pama poor integr acquisit
pressur econom uncertainti perform covanc increas competit
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
